Mumbai (Maharashtra) [India], April 25 (ANI/PR Newswire): Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company has launched a novel fixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This is the only available DPP4 and Glitazone combination brand in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) + Pioglitazone (15 mg), to be taken once a day.
Mumbai (Maharashtra) [India], October 26 (ANI): Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed drug combination for the management of type 2 diabetes.
\
\
\
\
